GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » Shiller PE Ratio

Nektar Therapeutics (Nektar Therapeutics) Shiller PE Ratio : (As of Apr. 30, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nektar Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Nektar Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Shiller PE Ratio Chart

Nektar Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nektar Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nektar Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Nektar Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Shiller PE Ratio falls into.



Nektar Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Nektar Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Nektar Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.22/129.4194*129.4194
=-0.220

Current CPI (Dec. 2023) = 129.4194.

Nektar Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.370 99.695 -0.480
201406 -0.260 100.560 -0.335
201409 0.530 100.428 0.683
201412 -0.350 99.070 -0.457
201503 0.250 99.621 0.325
201506 -0.400 100.684 -0.514
201509 -0.060 100.392 -0.077
201512 -0.400 99.792 -0.519
201603 -0.140 100.470 -0.180
201606 -0.360 101.688 -0.458
201609 -0.320 101.861 -0.407
201612 -0.280 101.863 -0.356
201703 -0.420 102.862 -0.528
201706 -0.390 103.349 -0.488
201709 0.370 104.136 0.460
201712 -0.210 104.011 -0.261
201803 -0.600 105.290 -0.738
201806 5.330 106.317 6.488
201809 -0.560 106.507 -0.680
201812 -0.570 105.998 -0.696
201903 -0.690 107.251 -0.833
201906 -0.630 108.070 -0.754
201909 -0.560 108.329 -0.669
201912 -0.640 108.420 -0.764
202003 -0.780 108.902 -0.927
202006 -0.450 108.767 -0.535
202009 -0.610 109.815 -0.719
202012 -0.650 109.897 -0.765
202103 -0.680 111.754 -0.787
202106 -0.690 114.631 -0.779
202109 -0.700 115.734 -0.783
202112 -0.790 117.630 -0.869
202203 -0.490 121.301 -0.523
202206 -0.850 125.017 -0.880
202209 -0.310 125.227 -0.320
202212 -0.320 125.222 -0.331
202303 -0.730 127.348 -0.742
202306 -0.270 128.729 -0.271
202309 -0.240 129.860 -0.239
202312 -0.220 129.419 -0.220

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nektar Therapeutics  (NAS:NKTR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Nektar Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics (Nektar Therapeutics) Business Description

Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Executives
Howard W Robin director, officer: President & CEO
Jonathan Zalevsky officer: Chief R&D Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson officer: SVP & General Counsel 1613 RAY DRIVE, BURLINGAME CA 94010
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner officer: Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen officer: VP & Chief Accounting Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Robert Chess director, officer: Executive Chairman
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie officer: SVP, COO & CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott officer: SVP & Chief Commercial Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer director 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau director 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein officer: Chief Scientific Officer 129 ELSIE STREET, SAN FRANCISCO CA 94110

Nektar Therapeutics (Nektar Therapeutics) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold Nektar Therapeutics Shares

By GuruFocus Research GuruFocus Editor 05-18-2023